TISIDB

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Cytoplasm, cytoskeleton, microtubule organizing center, centrosome Cytoplasm, cytoskeleton, spindle Note=Associated with centrosomes and the mitotic spindle during metaphase.
Domain	PF01979 Amidohydrolase family
Function	Necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. Plays a role in axon guidance, invasive growth and cell migration. May participate in cytokinesis.

> Gene Ontology [ TOP ]
Biological Process	GO:0000226 microtubule cytoskeleton organization GO:0007409 axonogenesis GO:0007411 axon guidance GO:0010721 negative regulation of cell development GO:0010975 regulation of neuron projection development GO:0010977 negative regulation of neuron projection development GO:0031345 negative regulation of cell projection organization GO:0032091 negative regulation of protein binding GO:0043393 regulation of protein binding GO:0045665 negative regulation of neuron differentiation GO:0048667 cell morphogenesis involved in neuron differentiation GO:0050768 negative regulation of neurogenesis GO:0051098 regulation of binding GO:0051100 negative regulation of binding GO:0051961 negative regulation of nervous system development GO:0061564 axon development GO:0097485 neuron projection guidance GO:1904529 regulation of actin filament binding GO:1904530 negative regulation of actin filament binding GO:1904616 regulation of actin binding GO:1904617 negative regulation of actin binding
Molecular Function	GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0031005 filamin binding
Cellular Component	GO:0005819 spindle

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-422475: Axon guidance R-HSA-399956: CRMPs in Sema3A signaling R-HSA-1266738: Developmental Biology R-HSA-373755: Semaphorin interactions

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CRMP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CRMP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CRMP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.34	0.00838
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.477	0.662
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.982	0.0373
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.036	0.947
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.037	0.984
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.135	0.958
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.109	0.798
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.069	0.946
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.465	0.623
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.853	0.457
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.874	0.22
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.01	0.959

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CRMP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CRMP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CRMP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CRMP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CRMP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CRMP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CRMP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CRMP1
Name	collapsin response mediator protein 1
Aliases	DPYSL1; CRMP-1; ULIP-3; dihydropyrimidinase-like 1; unc-33-like phosphoprotein 3; Dihydropyrimidinase-relate ......
Chromosomal Location	4p16.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CRMP1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CRMP1